Novel molecular targeted therapies for refractory thyroid cancer

Related Experiment Video

Updated: Jun 2, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Cesar A Perez1, Edgardo S Santos, Belisario A Arango

  • 1Cleveland Clinic Florida, Weston, Florida, USA.

Head & Neck
|May 6, 2011
PubMed

Insights

Thyroid cancer is increasing, with no cure for advanced types. Novel multi-kinase inhibitors targeting genetic pathways show promise in clinical trials for improved thyroid cancer treatment.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Thyroid cancer incidence is rising, representing the most frequent endocrine malignancy.
  • Current systemic treatments are ineffective for iodine-refractory differentiated or medullary thyroid carcinoma.
  • Understanding disease pathogenesis has identified key molecular targets for new therapies.

Purpose of the Study:

  • To review recent advances in understanding thyroid cancer pathogenesis.
  • To evaluate novel therapeutic agents targeting identified genetic alterations.
  • To discuss the potential impact of these agents on thyroid cancer management.

Main Methods:

  • Review of scientific literature on thyroid cancer genetics and targeted therapies.
  • Analysis of clinical trial data for novel agents targeting RET/PTC, B-Raf, and VEGFR-2 pathways.
  • Focus on multi-kinase inhibitors including axitinib, sorafenib, motesanib, and XL-184.

Main Results:

  • Key genetic alterations like RET/PTC rearrangements, B-Raf mutations, and VEGFR-2 pathways are crucial in thyroid cancer development.
  • Novel agents, particularly multi-kinase inhibitors, have demonstrated promising clinical responses and disease stabilization.
  • Axitinib, sorafenib, motesanib, and XL-184 show significant efficacy in preliminary studies.

Conclusions:

  • Targeted therapies are emerging as a promising strategy for managing advanced thyroid cancer.
  • Multi-kinase inhibitors represent a potential breakthrough in treating iodine-refractory differentiated and medullary thyroid carcinoma.
  • Ongoing randomized clinical trials are expected to redefine the treatment landscape for thyroid cancer.

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.